Freenome Lung Cancer Blood Test Wins FDA Breakthrough Device Status

What Happened

The U.S. Food and Drug Administration has granted breakthrough device designation to Freenome's investigational blood-based test, called SimpleScreen Lung, designed to triage high-risk adults for lung cancer screening. The designation, announced this week, accelerates the regulatory review process for a test that aims to identify candidates for low-dose CT lung cancer screening without requiring invasive procedures.

What the Designation Means

FDA breakthrough device designation is a program intended to speed development, assessment, and review of medical devices and diagnostics that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. The designation does not constitute FDA approval or clearance. It entitles the developer to more frequent and interactive communication with the FDA during the review process, which can shorten the overall timeline to a final regulatory decision.

SimpleScreen Lung is described as a blood-based test, meaning it works from a standard blood draw rather than tissue biopsy or imaging. Its stated purpose is to identify which high-risk adults should be directed toward low-dose CT screening, a step that could help prioritize screening resources and reduce unnecessary imaging.

About Freenome

Freenome is a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics, a term referring to the combined analysis of multiple biological data types such as genomics, proteomics, and other molecular signals. The company has previously advanced blood-based colorectal cancer screening tests and has positioned its platform as applicable across multiple cancer types.

Freenome's approach centers on detecting cancer-associated signals circulating in the blood, sometimes referred to as liquid biopsy, though the company applies computational methods to analyze patterns across multiple biomarker categories simultaneously.

Lung Cancer Screening Context

Lung cancer is among the leading causes of cancer-related death in the United States. Current screening guidelines from major medical bodies recommend annual low-dose CT scans for adults aged 50 to 80 who have a significant smoking history, but screening rates among eligible individuals remain low. A blood-based triage test, if validated and approved, could serve as an accessible first step to identify who among high-risk populations should proceed to imaging.

The SimpleScreen Lung test is investigational, meaning it is not yet available for clinical use outside of research or trial settings. Breakthrough device designation places it on an expedited regulatory track, but Freenome must still complete clinical validation studies and submit a full premarket approval or clearance application before the test could reach patients.

Broader Regulatory Activity in Cancer Blood Testing

The Freenome designation comes as regulatory attention to blood-based cancer detection is intensifying. Separately, GRAIL Inc. announced that an FDA advisory committee is scheduled to meet in September to evaluate the premarket approval application for its Galleri multi-cancer early detection blood test. GRAIL's Galleri test screens for more than 50 cancer types from a single blood draw and has been available on a limited commercial basis under a different regulatory pathway. The upcoming advisory committee review marks a significant step toward potential full FDA approval for that product.

The two developments reflect a broader wave of blood-based cancer diagnostics moving through the FDA review system, with multiple companies pursuing different technological approaches and regulatory strategies.

What Happens Next

Freenome is expected to engage in the FDA's expedited development and review process for SimpleScreen Lung, with the company required to conduct and submit clinical study data before a final approval determination can be made.